NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00136552,Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden,https://clinicaltrials.gov/study/NCT00136552,,COMPLETED,The purpose of this study is to assess in a prospective multicentric study (Phase III) the introduction of a monoclonal antibody directed against B-cells associated with a standard therapy including chemotherapy and alpha-interferon in first line treatment of patients with a large tumor burden follicular lymphoma.,NO,Lymphoma,DRUG: rituximab,Event free survival,Response rate|Overall survival,,Lymphoma Study Association,,ALL,"ADULT, OLDER_ADULT",PHASE3,360,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,FL2000|PHRC,2000-05,,2004-12,2005-08-29,,2007-07-03,"Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Hôpital Henri Mondor, Créteil, 94010, France|Hôpital Saint Louis, Paris, 75010, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, 69495, France|Centre Henri Becquerel, Rouen, 76038, France",
